United States · FDA National Drug Code directory
TAZICEF
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0409-5093_71a753fc-ae3d-4d94-bc72-a3a51a5bdd9a
- Product NDC
- 0409-5093
- Form
- INJECTION, POWDER, FOR SOLUTION
- Composition / generic term
- CEFTAZIDIME
- Labeler
- Hospira, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20060405 / 20260930
Source-listed ingredients
- CEFTAZIDIME — 2 g/1
These values do not establish equivalence or a dose recommendation.
Packages
- 10 VIAL, PATENT DELIVERY SYSTEM in 1 CARTON (0409-5093-11) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM (0409-5093-14) · 0409-5093-11
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →